Spruce Biosciences, Inc. shares recorded a significant increase, rising by 8.16% in a single day.

The recent stock price fluctuation was triggered by the company's announcement of a key breakthrough in the development of a drug targeting a rare pediatric brain disease, officially entering the stage of submitting an application to the U.S. Food and Drug Administration (FDA). This milestone event has sparked positive market expectations for the company's future commercialization prospects, boosting investor confidence. The drug targets a rare pediatric brain disease, and if ultimately approved by the FDA, it is expected to fill a gap in this therapeutic area.